Literature DB >> 12468327

Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma.

Mario M Leitao1, Murray F Brennan, Martee Hensley, Yukio Sonoda, Amanda Hummer, Dharmendra Bhaskaran, Ennapadam Venkatraman, Kaled Alektiar, Richard R Barakat.   

Abstract

OBJECTIVE: The objective was to determine long-term survival and predictors of outcome in a retrospective cohort of patients who underwent surgical resection of recurrent uterine leiomyosarcoma (LMS).
METHODS: Between January 1991 and March 2001, 41 patients who underwent surgical resection for recurrent uterine leiomyosarcoma were identified. The records of these patients were reviewed and abstracted data included patient age, date of initial diagnosis, tumor histology and grade, residual tumor after all operations, the use of adjuvant therapy, dates and sites of all recurrences, and disease status at last follow-up. Survival was determined from the time of first recurrence to last follow-up. Survival curves were estimated using the Kaplan-Meier method and P values were generated using the likelihood ratio test from the Cox proportional hazards model and chi(2) analysis.
RESULTS: Forty-one patients with recurrent uterine LMS (17 local pelvic, 18 distant, 6 both) underwent surgical resection at time of first recurrence. A thoracic procedure alone was performed in 13 cases. Information on residual disease was available for 37 patients. The disease-specific 2-year survival for all 41 patients was 71.2% (95% CI: 58.1, 87.3). In univariate analysis, time to first recurrence and optimal resection were significantly associated with longer overall survival.
CONCLUSION: Optimal surgical resection for recurrent uterine leiomyosarcoma may provide an opportunity for long-term survival in a select patient population. Time to first recurrence and optimal surgical resection were predictors of improved outcome in this study.

Entities:  

Mesh:

Year:  2002        PMID: 12468327     DOI: 10.1006/gyno.2002.6840

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  19 in total

Review 1.  A review of treatment of uterine leiomyosarcomas.

Authors:  Nicholas Reed
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

Review 2.  First-Line Therapy for Metastatic Soft Tissue Sarcoma.

Authors:  Megan Meyer; Mahesh Seetharam
Journal:  Curr Treat Options Oncol       Date:  2019-01-24

Review 3.  Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.

Authors:  Martee L Hensley; Brigitte A Barrette; Klaus Baumann; David Gaffney; Anne L Hamilton; Jae-Weon Kim; Johanna U Maenpaa; Patricia Pautier; Nadeem Ahmad Siddiqui; Anneke M Westermann; Isabelle Ray-Coquard
Journal:  Int J Gynecol Cancer       Date:  2014-11       Impact factor: 3.437

4.  Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.

Authors:  Paulina Cybulska; Vasileios Sioulas; Theofano Orfanelli; Oliver Zivanovic; Jennifer J Mueller; Vance A Broach; Kara C Long Roche; Yukio Sonoda; Martee L Hensley; Roisin E O'Cearbhaill; Dennis S Chi; Kaled M Alektiar; Nadeem R Abu-Rustum; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2019-06-12       Impact factor: 5.482

5.  Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas.

Authors:  Kenichi Nakamura; Hiroaki Kajiyama; Fumi Utsumi; Shiro Suzuki; Kaoru Niimi; Ryuichiro Sekiya; Jun Sakata; Eiko Yamamoto; Kiyosumi Shibata; Fumitaka Kikkawa
Journal:  Mol Clin Oncol       Date:  2018-01-19

6.  [Uterine sarcoma treatment].

Authors:  G Köhler
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

7.  Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).

Authors:  D Denschlag; F C Thiel; S Ackermann; P Harter; I Juhasz-Boess; P Mallmann; H-G Strauss; U Ulrich; L-C Horn; D Schmidt; D Vordermark; T Vogl; P Reichardt; P Gaß; M Gebhardt; M W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-10       Impact factor: 2.915

8.  Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019).

Authors:  Dominik Denschlag; Sven Ackermann; Marco Johannes Battista; Wolfgang Cremer; Gerlinde Egerer; Markus Follmann; Heidemarie Haas; Philipp Harter; Simone Hettmer; Lars-Christian Horn; Ingolf Juhasz-Boess; Karin Kast; Günter Köhler; Thomas Kröncke; Katja Lindel; Peter Mallmann; Regine Meyer-Steinacker; Alexander Mustea; Edgar Petru; Peter Reichardt; Dietmar Schmidt; Hans-Georg Strauss; Clemens Tempfer; Falk Thiel; Uwe Ulrich; Thomas Vogl; Dirk Vordermark; Paul Gass; Matthias W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-10-22       Impact factor: 2.915

Review 9.  The role of adjuvant therapy in uterine leiomyosarcoma.

Authors:  Jennifer A Ducie; Mario M Leitao
Journal:  Expert Rev Anticancer Ther       Date:  2015-11-26       Impact factor: 4.512

Review 10.  Isolated cutaneous metastasis of uterine leiomyosarcoma: case report and review of literature.

Authors:  Shane Corcoran; Aisling M Hogan; Tamas Nemeth; Fadel Bennani; Francis J Sullivan; Waqar Khan; Kevin Barry
Journal:  Diagn Pathol       Date:  2012-07-18       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.